Clinical Report: Rare (and Rarely Diagnosed) Diseases in Ophthalmology

Overview

Expand on the implications of the Orphan Drug Act beyond drug development, such as its impact on patient access.

Background

Rare diseases often receive less attention in drug development due to their limited patient populations, which can lead to high costs and challenges in clinical trial enrollment. The Orphan Drug Act and recent FDA initiatives aim to incentivize the development of therapies for these conditions. Understanding and diagnosing rare ophthalmic diseases is crucial for improving patient outcomes and ensuring timely access to effective treatments.

Data Highlights

No numerical data was provided in the source material.

Key Findings

• The Orphan Drug Act facilitates faster FDA review for drugs targeting diseases affecting fewer than 200,000 people.
• Tepezza, a treatment for thyroid eye disease, costs over $200,000 and was initially marketed to raise awareness of the condition.
• Cenegermin-bkbj (Oxervate) has shown to heal neurotrophic keratitis in 65%-72% of patients, yet many cases remain underdiagnosed.
• Keratoconus often goes unrecognized in early stages due to non-specific symptoms, leading to delayed treatment.
• New FDA guidelines emphasize the importance of genotype-informed diagnosis for rare diseases.

Clinical Implications

Suggest specific educational strategies or resources for healthcare professionals to improve recognition of rare diseases.

Conclusion

Reiterate the importance of ongoing research and collaboration among stakeholders in rare disease management.

References

1. Retinal Physician, Diabetic Retinopathy: The Masqueraders, 2010
2. Optometric Management, Understanding the Signs of Autoimmune Diseases, 2023
3. Retinal Physician, Lab Testing in Posterior Noninfectious Uveitis: What, When and Why?, 2011
4. Optometric Management, Digging in to Inherited Retinal Disease, 2025
5. AAO Clinical Assessment of Patients with Inherited Retinal Degenerations Guideline Summary, 2025
6. Uveal melanoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up, 2026
7. AAO Clinical Assessment of Patients with Inherited Retinal Degenerations Guideline Summary - Guideline Central
8. Uveal melanoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up - ScienceDirect
9. Current Opinion in Ophthalmology